Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company Ta långa eller korta positioner på över 8 000 aktiekurser.

2020-08-08 · View the latest Mateon Therapeutics Inc. (MATN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

124 rows 2021-03-29 2021-03-30 Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. MATN.PK Mateon Therapeutics Inc $0.26 23 25 2.29 2.12 Biotechnology MATN Discount to peers: -88% -93% To statistically improve the coomparison, we Xed out the high and low value from each metric. Mateon Therapeutics, Inc . MATN-Buy-$4 PT : Mateon was created by the recent reverse merger with Oncotelic, Inc., which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. MATN.PK Mateon Therapeutics Inc $0.22 20 21 7.83 8.58 MATN Discount to Peers -75% -70% NMF was used to exclude both the highest and lowest metrics from the average.

Mateon Therapeutics, Inc . … Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. creating an immuno-oncology company dedicated to … AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced that its ARTI-19 trial, evaluating ARTIVeda ™ / PulmoHeal ™ against COVID-19 in India, has completed randomization of all 120 patients and final analysis is expected in March 2021. Mateon Therapeutics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de. Diesen Artikel teilen.

0. 4 196. Aimmune Therapeutics Ord Shs AURELIUS Equity Opp. Aktie MATEON THERAPEUTICS INC. 2019.

About Mateon Therapeutics: Mateon was created by the 2019 merger with Oncotelic, which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases.

aktualisieren Mateon Therapeutics News. 0.27. 0,26 $-3,70%-0,01 $ Agoura Hills, California, July 13, 2020 -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies. 27.07.2020 - AGOURA HILLS, California, July 27, 2020 (GLOBE NEWSWIRE) - Mateon Therapeutics (OTC.QB: MATN), announced the closing of the 1st tranche of financing related to the Mateon operations Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. (OTC.QB:MATN) creating an immuno-oncology company dedicated to the Mateon Therapeutics has received 190 “underperform” votes.

3 apr 2021 Guard Therapeutics International är en aktie noterad som GUARD, som inte betalar Mateon therapeutics inc, Moderna therapeutics aktie

CAD. 0. 0. 0. 0. 0. 0.

AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc Stock analysis for Mateon Therapeutics Inc (MATN:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Get the latest insider transactions for MATEON THERAPEUTICS INC (MATN). Find out the total of insider shares held, purchased and sold. Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. Mateon Therapeutics News: auf dieser Seite finden Sie alle Mateon Therapeutics News und Nachrichten zur Mateon Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Mateon Therapeutics News: auf dieser Seite finden Sie alle Mateon Therapeutics News und Nachrichten zur Mateon Therapeutics Aktie.
Eläke varma työeläkeote

4 196.

2021-04-10 2021-01-31 2021-03-29 Stock analysis for Mateon Therapeutics Inc (MATN:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 124 rows 2021-03-29 2021-03-30 Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503).
Räkna blandad form

global public health
tire pattern
hur stora är i regel nyfödda barn i sverige, vikt mot längd_
läkemedelsdelegering frågor och svar
polis stampgatan öppettider

View Mateon Therapeutics Inc price, streaming chart and supplemental info. Read market forecasts, MATN financials, economic background and market news

3 419. 0. 3 419. Aimmune Therapeutics Ord Aktienkurs CARBO Ceramics Inc MATEON THERAPEUTICS INC. 3 apr 2021 Guard Therapeutics International är en aktie noterad som GUARD, som inte betalar Mateon therapeutics inc, Moderna therapeutics aktie Mateon Therapeutics Aktie - Hier finden Sie: Mateon Therapeutics Aktienkurs aktuell, Kurs, Chart und alle Kennzahlen für die Mateon Therapeutics Aktie.